Biotech & Bioprocessing

Modern oncology is currently witnessing a profound shift as the mechanical precision of protein engineering finally catches up to the complex biological reality of the human immune system. For years, the promise of T-cell engagers (TCEs) was restricted to blood-borne malignancies where the targets

The current landscape of biological production is frequently hampered by a fundamental misalignment between the engineering of high-performing microbial strains and the logistical realities of industrial-scale purification processes. This systemic failure often manifests when a strain that performs

The landscape of gastrointestinal oncology has shifted significantly as European regulators authorize a potent new weapon for combating aggressive tumors before they have the chance to spread. The European Commission has officially approved the use of AstraZeneca’s durvalumab, commercially known as

The landscape of hematologic oncology has long been a battlefield where patients and physicians fight a grueling war of attrition against diseases that are managed but rarely defeated. For those living with rare myeloproliferative neoplasms, the medical journey often feels like a series of

The therapeutic landscape for multiple myeloma has long been defined by a relentless cycle of remission and relapse, leaving many patients with few options once primary defenses fail. Teclistamab, marketed as Tecvayli, has emerged as a transformative solution to this exhaustion, functioning as a

The landscape of modern medicine is currently shifting as BioNTech SE initiates a monumental transformation by separating its core operations into two distinct entities. This strategic pivot involves the launch of an independent biotechnology firm that will focus exclusively on pioneering